352 related articles for article (PubMed ID: 20044844)
1. Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.
Diehl JL; Daw JR; Coley KC; Rayburg R
J Manag Care Pharm; 2010; 16(1):23-31. PubMed ID: 20044844
[TBL] [Abstract][Full Text] [Related]
2. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.
Buckley BC; Roylance D; Mitchell MP; Patel SM; Cannon HE; Dunn JD
J Manag Care Pharm; 2010; 16(1):15-22. PubMed ID: 20044843
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis.
Frogel MP; Stewart DL; Hoopes M; Fernandes AW; Mahadevia PJ
J Manag Care Pharm; 2010; 16(1):46-58. PubMed ID: 20131495
[TBL] [Abstract][Full Text] [Related]
4. Respiratory syncytial virus morbidity and outpatient palivizumab dosing in South Carolina, 2004-2009.
Chadha AD; Bao W; Holloway J; Mann J; Rye AK; Brown DE
South Med J; 2012 Aug; 105(8):399-404. PubMed ID: 22864095
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of a novel web-based prior approval application for palivizumab prophylaxis of respiratory syncytial virus in a state Medicaid program.
Lundeen K; Pfeiffenberger T; Jacobson Vann J; O'Brien T; Sampson C; Wegner S
J Manag Care Pharm; 2013 Mar; 19(2):115-24. PubMed ID: 23461427
[TBL] [Abstract][Full Text] [Related]
6. Association of RSV-related hospitalization and non-compliance with palivizumab among commercially insured infants: a retrospective claims analysis.
Stewart DL; Ryan KJ; Seare JG; Pinsky B; Becker L; Frogel M
BMC Infect Dis; 2013 Jul; 13():334. PubMed ID: 23870086
[TBL] [Abstract][Full Text] [Related]
7. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
[TBL] [Abstract][Full Text] [Related]
9. Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.
Wegner S; Vann JJ; Liu G; Byrns P; Cypra C; Campbell W; Stiles A
Pediatrics; 2004 Dec; 114(6):1612-9. PubMed ID: 15574623
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the timing of initial prophylactic palivizumab dosing on hospitalization of neonates for respiratory syncytial virus.
Ohler KH; Pham JT
Am J Health Syst Pharm; 2013 Aug; 70(15):1342-6. PubMed ID: 23867491
[TBL] [Abstract][Full Text] [Related]
11. Impact of the 2014 American Academy of Pediatrics recommendation and of the resulting limited financial coverage by the Italian Medicines Agency for palivizumab prophylaxis on the RSV-associated hospitalizations in preterm infants during the 2016-2017 epidemic season: a systematic review of seven Italian reports.
Cutrera R; Wolfler A; Picone S; Rossi GA; Gualberti G; Merolla R; Del Vecchio A; Villani A; Midulla F; Dotta A
Ital J Pediatr; 2019 Nov; 45(1):139. PubMed ID: 31706338
[TBL] [Abstract][Full Text] [Related]
12. Partial palivizumab prophylaxis and increased risk of hospitalization due to respiratory syncytial virus in a Medicaid population: a retrospective cohort analysis.
Krilov LR; Masaquel AS; Weiner LB; Smith DM; Wade SW; Mahadevia PJ
BMC Pediatr; 2014 Oct; 14():261. PubMed ID: 25308481
[TBL] [Abstract][Full Text] [Related]
13. Compliance with prophylaxis for respiratory syncytial virus infection in a home setting.
Golombek SG; Berning F; Lagamma EF
Pediatr Infect Dis J; 2004 Apr; 23(4):318-22. PubMed ID: 15071285
[TBL] [Abstract][Full Text] [Related]
14. A cost-benefit analysis of RSV prophylaxis in high-risk infants.
Schrand LM; Elliott JM; Ross MB; Bell EF; Mutnick AH
Ann Pharmacother; 2001 Oct; 35(10):1186-93. PubMed ID: 11675842
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of respiratory syncytial virus prophylaxis in various indications.
Hampp C; Kauf TL; Saidi AS; Winterstein AG
Arch Pediatr Adolesc Med; 2011 Jun; 165(6):498-505. PubMed ID: 21300647
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
17. Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants.
Curtiss FR; Fairman KA
J Manag Care Pharm; 2010; 16(1):59-66. PubMed ID: 20044846
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States.
Weiner LB; Masaquel AS; Polak MJ; Mahadevia PJ
J Med Econ; 2012; 15(5):997-1018. PubMed ID: 22435648
[TBL] [Abstract][Full Text] [Related]
19. Improved outcomes with home-based administration of palivizumab: results from the 2000-2004 Palivizumab Outcomes Registry.
Frogel M; Nerwen C; Boron M; Cohen A; VanVeldhuisen P; Harrington M; Groothuis J;
Pediatr Infect Dis J; 2008 Oct; 27(10):870-3. PubMed ID: 18776822
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]